A bold revelation: a common constipation medication may actually guard kidney health. Chronic kidney disease (CKD) affects people worldwide and frequently progresses to a stage where regular dialysis becomes essential. Even though CKD is widespread and impactful, there are currently no approved drugs that can actively restore lost kidney function. In a groundbreaking turn, a research team led by Professor Takaaki Abe from Tohoku University’s Graduate School of Medicine repurposed a constipation drug and found that it can slow CKD progression. This study marks the first time lubiprostone has been shown to help preserve kidney function in CKD patients.
Abe explains the rationale: constipation is a frequent companion of CKD, and by exploring this link, the team suspected that treating constipation could, in turn, benefit kidney health. The logic is that constipation disrupts the gut microbiota, which can worsen kidney function. By addressing constipation, they hypothesized, kidney function could be protected.
Clinical trial evidence supports the idea. A multicenter Phase II study (LUBI-CKD TRIAL) was conducted across nine medical centers in Japan, enrolling 150 participants with moderate CKD. Researchers compared lubiprostone at 8 µg and 16 µg doses against a placebo. Over the trial period, individuals receiving lubiprostone exhibited a slower decline in kidney function, as measured by the estimated glomerular filtration rate (eGFR), a standard gauge of renal performance.
Beyond the clinical outcomes, the team investigated the mechanism behind the protective effect. They discovered that lubiprostone boosts the production of spermidine, a compound that enhances mitochondrial function by promoting helpful gut bacteria. This improved mitochondrial activity correlated with a renoprotective effect, helping to limit further kidney damage.
Future directions and personalized care
Looking ahead, the researchers plan a Phase 3 trial with a larger participant pool to validate the findings. They also aim to identify biomarkers that can help predict which patients are most likely to benefit, with the ultimate goal of tailoring CKD treatment to the individual. This represents a meaningful shift from current CKD therapies, which predominantly target toxin reduction rather than function restoration.
Overall, the study suggests that certain laxatives may slow kidney deterioration and could pave the way for new approaches to conditions marked by mitochondrial dysfunction. The full study appears in Science Advances.
Would you consider a constipation medication as part of CKD management if further research confirms these results, or do you think this approach could divert attention from other proven treatments? Share your thoughts in the comments.
